Comprehensive genomic profiling of renal-cell carcinoma (RCC) metastases was successfully performed via a targeted next-generation sequencing panel on specimens derived from patients in a phase 2 biomarker study of the allosteric mTOR inhibitor everolimus. Alterations in the PI3K-AKT-mTOR pathway were common in metastatic RCC tumors. One partial response occurred in a patient with an mTOR mutation of unclear significance. Introduction: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus. Patients and Methods: An open-label, single-arm phase 2 biomarker study of everolimus 10 mg daily was conducted in metastatic RCC patients. Needle biopsy or metastasectomy was performed on metastatic tumors before everolimus initiation. Next-generation sequencing was performed using a targeted hybrid capture panel detecting alterations within exons and key introns of ! 300 cancer-associated genes. Disease assessments were obtained every 8 weeks using standard radiographic modalities and evaluated by Response Evaluation Criteria in Solid Tumors criteria. Results: Objective response was seen in 1 (4.2%) of 24 patients. Two patients (8.3%) had stable disease lasting > 6 months. Median (90% confidence interval) overall and progression-free survival were 20.1 (8.6, NA) and 3.8 (2.4, 5.4) months, respectively. Next-generation sequencing was successful on 18 pretreatment specimens and 3 on-treatment specimens. Alterations in the phosphatidylinositol 3-kinaseeprotein kinase Bemammalian target of rapamycin (PI3K-AKT-mTOR) pathway were identified in 8 (44%) of 18 pretreatment samples. An mTOR E2419D mutation was identified in the patient who experienced partial response. Alterations in VHL, PBRM1, SETD2, KDM5C, and ATM were common in the RCC metastases before initiation of everolimus. Conclusion: Nearly half of heavily pretreated RCC metastases may harbor mutations in components of the PI3K-AKT-mTOR pathway. Commonly mutated genes in primary RCC were also altered at a high frequency in RCC metastases.
Introduction
Renal cell carcinoma (RCC) is the most common type of adult kidney cancer and has increased in incidence over the past several decades. 1 The treatment armamentarium against RCC has expanded greatly over the past decade, with approvals of multiple targeted therapies against the vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways as well as immune checkpoint inhibition targeting programmed cell death protein 1 (PD-1). 2 Therapeutic targeting of mTOR is particularly appealing, as components of the phosphatidylinositol 3-kinaseeprotein kinase Bemammalian target of rapamycin (PI3K-AKT-mTOR) signaling pathway are altered in approximately 28% of RCC samples. 3 Everolimus is an allosteric mTOR inhibitor with proven clinical activity against metastatic RCC (mRCC). A randomized, doubleblind, placebo-controlled trial of everolimus in mRCC patients with prior disease progression while receiving VEGF-targeted therapy showed improved progression-free survival (PFS) of 4.9 versus 1.9 months, leading to approval by the US Food and Drug Administration. 4 However, despite improvements in PFS and overall survival (OS) with allosteric mTOR inhibitors in randomized trials, clinical benefit is limited, with most patients displaying stable disease and less than 10% of patients experiencing partial response. 5, 6 Several studies have attempted to identify biomarkers that may predict the subset of patients who may respond well to mTOR inhibition. In particular, genomic alterations along the PI3K-AKTmTOR pathway have been an area of focus as mutations in mTOR, TSC1, and TSC2 have been found in case reports and small case series to be associated with improved response to mTOR inhibition in RCC and other tumor types. [7] [8] [9] [10] [11] [12] However, the largest series in RCC patients found that while somatic mutations in mTOR pathway genes were more common in patients whose disease responded to mTOR inhibitors than those whose disease did not, a large proportion of those with responsive disease had no alterations in mTOR pathway genes, and several patients with mTOR pathway mutations had disease that was nonresponsive to mTOR inhibitor therapy. 12 Other studies in RCC have examined the correlation between common RCC mutations in PBRM1, BAP1, SETD2, and KDM5C and response to everolimus in the first-line setting. 13 These studies investigated genomic alterations predominantly in primary tumor samples. Given the documented intratumoral heterogeneity of RCC, metastatic tumors may harbor a very different genomic profile not previously seen in studies using nephrectomy specimens. We report here the results of comprehensive genomic profiling via a targeted next-generation sequencing (NGS) panel of cancerassociated genes performed on the metastatic tumors of patients enrolled onto a phase 2 trial of everolimus for advanced RCC. We aimed to characterize the genomic profile of mRCC lesions and evaluate whether alterations in critical genes in the PI3K-AKTmTOR pathway or other common alterations in RCC may be associated with clinical benefit from everolimus.
Patients and Methods

Patients and Study Design
An open-label, single-arm phase 2 trial of everolimus with pretreatment biopsy of a metastatic lesion or metastasectomy was conducted in patients with advanced RCC (NCT00827359). Key eligibility criteria included Eastern Cooperative Oncology Group performance status of 1; no prior treatment with mTOR inhibitors; age 18 years or older; and adequate kidney, liver, and bone marrow function. Patients were also required to have a safely accessible site of metastatic disease for biopsy and at least one additional site of measurable disease. A subset of patients was asked to undergo an on-treatment biopsy of the same metastatic lesion between days 7 to 14 after initiation of everolimus. The ontreatment biopsy was not a requirement for participation in the trial. All patients received everolimus 10 mg by mouth daily for each 28-day cycle and continued treatment until disease progression, intolerable toxicity, or withdrawal of consent. The trial accrued patients at 3 major academic cancer centers-Beth Israel Deaconess Medical Center (Boston, MA), Dana-Farber Cancer Institute (Boston, MA), and Duke University Cancer Center (Durham, NC)-and was approved by their respective institutional review boards.
The original primary objective of the trial was to prospectively validate the expression of phospho-Akt and phospho-S6 as predictive biomarkers of response to everolimus by measure of PFS. However, phospho-Akt and phospho-S6 immunohistochemistry was unsuccessful as a result of the lack of adequate tissue samples and was not pursued further. One secondary end point was to develop a genomic predictor of response to everolimus that was based on microarray analysis of pretreatment biopsy samples. The secondary end point was subsequently modified to use comprehensive genomic profiling of metastatic tumors via a targeted NGS panel to evaluate whether PI3K-AKT-mTOR pathway alterations in mRCC tumors may predict for response to everolimus.
Twenty-five patients enrolled onto the study between April 2009 and November 2012. One patient became ineligible because of the inability to obtain a pretreatment biopsy sample. A total of 27 tissue samples were successfully obtained from 24 patients, with 3 sets of paired tissues obtained before treatment and while receiving treatment. Targeted NGS was successful in 21 samples from 19 patients, including 2 pairs of pretreatment and on-treatment tissues and 1 on-treatment sample from a patient whose pretreatment sequencing was unsuccessful. Of the 18 patients who had sequencing from pretreatment tissue available, 4 discontinued treatment because of unacceptable toxicity. Therefore, the analyses of genomic predictors of response to everolimus include 14 patients who had pretreatment NGS of metastatic tumor and for whom response data were available.
Tumor Assessments
Objective tumor response was determined every 8 AE 1 weeks on study by either computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients who left the study had evaluations performed at the time of everolimus discontinuation and before initiation of other therapies. All patients, including those who discontinued therapy early, were followed for response until progression and for survival for 2 years from the date of registration. Following off-study visit, the study team updated survival data every 6 months for up to 3 years. Best overall response was determined by
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Genomic Profiling in RCC the maximal tumor shrinkage recorded from patient registration until disease progression or recurrence. Partial response was confirmed by repeat assessments performed no less than 4 weeks later. The final analyses data cutoff date was January 11, 2018.
Next-Generation Sequencing
Targeted NGS was performed via an institutional hybrid capture panel.
14,15 DNA was extracted from archival formalin-fixed paraffin-embedded tumor samples containing at least 20% tumor nuclei and analyzed by massively parallel sequencing with a solution-phase Agilent SureSelect hybrid capture kit and Illumina HiSeq 2500 sequencer. The panel detects mutations, insertions, deletions, copy number changes, and rearrangements within exons of 300 cancer-associated genes and 113 key introns of 35 cancerassociated genes (Supplemental Table 1 in the online version). Genes involved in the PI3K-AKT-mTOR pathway captured by the NGS panel include: PIK3C2B, PIK3CA, PIK3CG, PIK3R1, PTEN, TSC1, TSC2, mTOR, RHEB, RPTOR, NPRL2, NPRL3, NF1, NF2, FLCN, RICTOR, DEPDC5, and STK11. Genes commonly altered in RCC captured by the panel include: VHL, PBRM1, SETD2, KDM5C, BAP1, TP53, ATM, and ARID1A.
Statistical Analysis
PFS was defined as the time from date of registration onto the study to time of disease progression or death from any cause. Patients who were alive and free of progression were censored at the date of last disease assessment without evidence of progression. OS was defined as the time from study registration to death from any cause. Patients who were alive were censored at the date of last contact. Overall response was defined as the proportion of patients achieving complete or partial response to treatment per RECIST criteria.
Measures of frequencies and proportion were used to describe categorical variables; and measures of dispersion for continuous variables. Kaplan-Meier method, with 90% log-log confidence interval (CI), was used to describe time-to-event end points (PFS and OS). Log-rank test was used to assess difference in these end points by levels of categorical variables. Cox proportional hazards model was used for univariate and multivariate modeling of the impact of predictors on time-to-event end points.
Results
Patient Characteristics
Baseline patient characteristics are summarized in Table 1 . The study closed early because of low accrual after enrolling 25 patients. One of the enrolled patients was ineligible according to the trial The site of most frequent metastases was lung (67%), followed by intra-abdominal lymph nodes (46%).
Treatment Response and Toxicity
The median (range) number of everolimus cycles started and completed was 4 (1-22) and 4 (0-21), respectively. The median (90% CI) OS and PFS were 20.1 (8.6, NA) and 3.8 (2.4, 5.4) months, respectively (Figure 1 ). Median (90% CI) duration of stable disease was 3.9 (2.1, 48.4) months. There was no statistically significant difference (at the 5% level) in baseline demographic variables between patients with successful NGS on pretreatment biopsy sample analysis (n ¼ 18) and those without (n ¼ 6). Overall response rate (90% exact CI) was 4.2 (0.2, 18.3) % (Table 2 ). Best overall response by RECIST criteria included a partial response in 1 patient, stable disease in 17 patients, and progressive disease in 3 patients. Two (8.3%) of 24 patients had stable disease lasting greater than 6 months.
Sixteen patients (67%) had toxicity-related events. Table 3 shows treatment-related toxicities of any grade defined using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. There were no treatment-related grade 4 or 5 toxicities. Five treatment-related grade 3 toxicities were reported, each occurring in different CTCAE categories: anorexia, diarrhea, fatigue, stomatitis, and renal failure. The most frequent grade 2 toxicity was limb edema. The most frequent grade 1 toxicities include rash (n ¼ 16), hypertriglyceridemia (n ¼ 14), and stomatitis (n ¼ 12). Approximately 67% of patients discontinued treatment because of disease progression and 21% (n ¼ 5) because of unacceptable toxicity (Supplemental Table 2 in the online version).
PI3K-AKT-mTOR Pathway Alterations
A summary of the key genomic findings is shown in Figure 2 . NGS was successful on 18 pretreatment specimens and 3 ontreatment specimens with a mean (range) coverage of 265 (74-405) reads across all targeted exons. Mutations in the PI3K-AKT-mTOR pathway were identified in 8 (44%) of 18 patients who had successful NGS from pretreatment metastatic tissue specimens. PI3K-AKT-mTOR pathway mutations included mTOR S2215Y, mTOR E2419D, PIK3CA D152H, PIK3CA H1047R, PIK3C2B R221C, PIK3C2B R672Q, PTEN A34Lfs*20, NPRL3 V549M, DEPDC5 S1123F, and FLCN I172T (Supplemental Table 3 in the online version). Two pretreatment samples carried multiple alterations in PI3K-AKT-mTOR pathway genes. There was no difference in PFS between patients with and without mutation in the PI3K-AKT-mTOR pathway (Supplemental Figure 1 in the online version). Similarly, there was no difference (Wilcoxon Rank Sum test P ¼ .610) in the percentage change in tumor diameter between patients with and without mutation in the PI3K-AKT-mTOR pathway (Figure 3 ). Best overall response for patients with PI3K-AKT-mTOR pathway mutations included 6 cases of stable disease, 1 case partial response, and 1 unevaluable case. The patient who experienced partial response on everolimus had a PFS of 7 months and harbored an mTOR E2419D mutation. One of the patients with PI3K-AKT-mTOR pathway mutations (FLCN I172T) discontinued treatment because of toxicity. None of the patients with PI3K-AKT-mTOR pathway mutations in the pretreatment metastatic lesions underwent an on-treatment biopsy, and there were no PI3K-AKT-mTOR pathway mutations identified in the 3 posttreatment biopsy specimens. Genomic Profiling in RCC
Common Gene Alterations in RCC
Genes known to be commonly mutated in primary clear-cell RCC were also found to be significantly altered in our pretreatment metastatic lesions, including VHL (10 patients; 56%), PBRM1 (10; 56%), SETD2 (6; 33%), KDM5C (4; 22%), ATM (3; 17%), ARID1A (2; 11%), BAP1 (1; 6%), and TP53 (1; 6%) (Supplemental Table 3 in the online version). There was a high concordance between mutations in VHL and PBRM1, with 8 pretreatment metastatic lesions harboring mutations in both genes. Mutations in SETD2 occurred alongside mutations in PBRM1 in 5 of 6 cases. All 4 cases with mutations in KDM5C also carried mutations in VHL.
Metastatic Genomic Profiles During Treatment
One patient who had paired pretreatment and on-treatment sequencing information harbored mutations in VHL, KDM5C, and BAP1 that were maintained in both specimens. Interestingly, the pretreatment specimen also had a TP53 mutation that was lost in the on-treatment sample. The second case with paired sequencing information showed similar results before and while receiving treatment: NPRL3 and PIK3C2B alterations were identified both samples and in a similar proportion of reads. One patient who had sequencing performed on-treatment only and did not have pretreatment sequencing had alterations in PBRM1, BAP1, ARID1A, and TP53.
Discussion
While comprehensive genomic profiling has significantly enhanced understanding of the molecular drivers and vulnerabilities of human cancers, the vast majority of such studies in RCC have been performed on primary tumor specimens and may not be fully representative of the molecular landscape of advanced disease given the well-documented intratumoral heterogeneity within RCC. [16] [17] [18] Nonetheless, large studies like those conducted by The Cancer Genome Atlas have shown a high frequency of PI3K-AKT-mTOR pathway mutations in primary RCC tumors, prompting interest in using genomic profiling to identify predictive biomarkers for mTOR inhibitors. One study utilizing mostly primary nephrectomy specimens found mTOR pathway mutations to be more common in patients who responded to mTOR inhibitors, but a significant number of responding patients did not harbor any alterations in the mTOR pathway. 12 Another study found that mutations in PBRM1
and BAP1 in primary nephrectomy specimens were associated with longer and shorter PFS, respectively, with first-line everolimus. 13 With the emergence of immune checkpoint inhibitors and newer antiangiogenic therapies, mTOR inhibitors are now more 
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Clinical Genitourinary Cancer October 2018 -345 commonly used in heavily pretreated patients. Therefore, assessment of the genomic profile of metastatic tumors immediately before treatment initiation would more likely capture associations between molecular alterations and treatment response. Our study characterizes the genomic landscape of RCC metastases from patients who have been heavily treated with systemic therapies and 
asks whether molecular alterations in the mTOR pathway or other commonly mutated genes in RCC may correlate with response to everolimus. We defined PI3K-AKT-mTOR pathway genes as those directly on pathway or well-characterized regulators of mTOR signaling that are captured by our targeted NGS panel. Nearly half of the patients in our study were found to have genomic alterations affecting the PI3K-AKT-mTOR pathway, including 10 distinct alterations in 7 genes. Overall, there was no association between presence of a PI3K-AKT-mTOR pathway alteration and clinical outcome, particularly given the low response rate and small sample size of our study. The single patient who experienced a partial response to everolimus harbored an mTOR E2419D mutation in the pretreatment metastatic specimen. The mTOR E2419K mutation is a well-characterized activating mutation in the mTOR kinase domain previously described in a case report of a patient with urothelial carcinoma who experienced a long-lasting complete response to everolimus and the VEGF inhibitor pazopanib. 11 While the glutamic acid to lysine substitution in mTOR E2419K results in constitutive activation of mTOR signaling, it is not clear that the glutamic acid to aspartic acid change found in our study would confer a similar functional change. In fact, glutamic acid to aspartic acid changes are conservative mutations that typically preserve biochemical function. Further studies may be helpful to elucidate the functional relevance of the mTOR E2419D mutation. The heavily pretreated patients in our study are likely representative of real-world mRCC patients currently receiving mTOR inhibitors. Patients derived a modest clinical benefit from everolimus similar to the reported efficacy from larger randomized studies. The RECORD-1 trial demonstrated a clinical benefit of everolimus over placebo in patients with mRCC. Patients treated with everolimus experienced a median PFS of 4.9 months, but the overall response rate was only 1.8%. 6 Subsequently, the METEOR and CheckMate 025 trials showed cabozantinib and nivolumab, respectively, to be superior to everolimus, with the mTOR inhibitor providing a similar PFS of 3.8 to 4.4 months and overall response rate of 5% in both studies. 19, 20 Our study showed a comparable PFS of 3.8 months and overall response rate of 4.2% with singleagent everolimus. Discontinuation of treatment because of unacceptable toxicity occurred in 5 patients (21%) in our study, a rate that is slightly higher than the 9% to 13% reported in the large randomized trials. However, no grade 4 or 5 toxicities occurred in our study. Furthermore, the grade 3 toxicities in our trial included well-defined adverse events related to mTOR inhibitors, including anorexia, diarrhea, fatigue, stomatitis, and renal failure. No unexpected adverse events were observed in our study. No specific genomic alteration appeared to be enriched in the patients who discontinued everolimus because of toxicity.
We acknowledge several limitations. First, the small number of patients enrolled onto the clinical trial limited the number of cases of successful NGS performed on metastatic specimens. Second, follow-up on-treatment biopsies were not mandatory, and we thus did not have many pretreatment and on-treatment paired specimens for analysis. Third, genomic profiling was not performed on the primary nephrectomy specimens of patients enrolled onto the current study, and we are therefore unable to compare the molecular profile of RCC metastases with primary tumors over time. Finally, we did not analyze normal tissue and therefore cannot determine whether any of the alterations seen in the metastatic specimens were somatic versus germline.
Several factors may account for the low response rate to everolimus despite the relatively high prevalence of PI3K-AKT-mTOR pathway alterations in our study. First, it is possible that only a fraction of the genomic alterations in this pathway confers functional hyperactivation of mTOR signaling, and are bona fide oncogenic drivers. Second, in cancers driven by PI3K-AKT-mTOR pathway alterations, everolimus monotherapy may be ineffective because of its limited activity in inhibiting only the mTORC1 complex, and only some downstream effectors (eg, S6K) and not others (eg, 4EB-P1). Third, multiple inducible feedback loops exist within the PI3K-AKT-mTOR pathway and may allow cells to bypass allosteric mTOR inhibition. 21 Finally, it is possible that newer adenosine triphosphateecompetitive inhibitors of the mTOR kinase domain that fully inhibit both the mTORC1 and mTORC2 complexes may be more effective than allosteric mTOR inhibition by everolimus. Such mTOR kinase inhibitors are currently in clinical development.
Although an association between PI3K-AKT-mTOR pathway alterations and response to mTOR inhibitors was not seen in this study, a previous study by some of the authors here that examined much larger numbers of responding patients indicated that mutations in mTOR, TSC1, or TSC2 were more common in patients who derived clinical benefit from allosteric mTOR inhibitors than in those who progressed. 12 Nonetheless, many patients with mTOR, TSC1, or TSC2 mutations did not respond to mTOR inhibition, and many patients who responded to mTOR inhibition did not have mTOR, TSC1, or TSC2 mutations in their tumors. The present study is of smaller size and did not include many patients with therapy-responsive disease, so the statistical power is inadequate to 
Clinical Genitourinary Cancer October 2018 -347 associate pathway alterations with therapeutic response. On the basis of the available data, we do not presently advocate routine genotyping of RCC biopsy samples to drive clinical decisionmaking. However, if such information is available and a PI3K-AKT-mTOR pathway alteration is identified, it may be reasonable to consider mTOR inhibitor monotherapy or the combination of everolimus plus lenvatinib over other potential treatment options using appropriate clinical judgment.
Conclusion
In conclusion, we present one of the first reports of comprehensive genomic profiling of RCC metastases and show that genomic alterations involving the PI3K-AKT-mTOR pathway and other commonly altered RCC genes are very common in this heavily pretreated patient population. We hope that our results will help to guide future studies on kidney cancer biology and therapeutic targeting of the PI3K-AKT-mTOR pathway.
Clinical Practice Points
Genomic alterations and hyperactivation of the PI3K-AKTmTOR pathway are common features of RCC. The allosteric mTOR inhibitor everolimus has shown limited efficacy in patients with mRCC, with small subsets of patients experiencing significant responses in their tumors. While several prior studies have attempted to identify genetic alterations in RCC that may be predictive of response to mTOR inhibitors, our study is the first to examine exclusively metastatic tumors rather than primary nephrectomy specimens. Alterations in the PI3K-AKT-mTOR pathway are indeed common in RCC metastases, occurring in 44% of pretreatment samples in our study. Response to everolimus occurred in 1 (4.2%) of 24 patients. Two patients (8.3%) had stable disease lasting > 6 months. The lone responding patient had a metastatic tumor with an mTOR E2419D mutation of unclear significance. There was no significant association between the presence of PI3K-AKT-mTOR pathway gene alterations and PFS. Further studies on specific PI3K-AKT-mTOR pathway alterations or gene or protein expression level analyses in metastatic specimens may identify more robust predictive biomarkers for mTOR inhibitor therapy in patients with mRCC.
